



# Real World Efficacy of Antiviral Therapy in Chronic Hepatitis C in New Zealand

Sarah Middleton

Assoc Prof Catherine Stedman

Prof Ed Gane

# Objective

- NZ has the largest 'Real World' experience of VIEKIRA PAK, with 30% all patients treated in community
- REACH-C database will review patterns of prescription, uptake and outcomes.
  - Inform HCV-infected community and GPs on the safety and efficacy of short duration DAAs.
  - Inform PHARMAC on rate of treatment failure to determine need for retreatment regimen.
  - Pave the way for future pan-genotypic DAAs in primary and secondary care.

# Method


- Prescription data provided by PHARMAC (July 2016 – June 2018) on 3000 patients who have received VIEKIRA PAK.
- Baseline and outcome data obtained from DHBs, GP practices, community and reference labs.
- Impact of baseline predictors on treatment uptake and SVR.
  - Demographics
  - HCV genotype 1 subtype
  - Cirrhosis status
  - Previous treatment

# Method

- This is interim analysis of data obtained from 1487 patients treated in 9 DHBs
  - Auckland, Bay of Plenty, Canterbury, Counties-Manukau, Nelson-Marlborough, Northland, Southern, Waikato and Waitemata DHBs.


# Age, Gender Distribution

n = 1487




- Median Age **M**: 55-59 years, **F**: 50-54 years
- Male gender 65%

# Ethnicity (n=1487)




# Cirrhosis status

- Determination of cirrhosis
  - Elastography: LSM >12.5 Kpa
  - APRI score: >1.0
  - Imaging
  - Other




# HCV Genotype subtype






# Sustained Virological Response


- To date - SVR data obtained for 1244 patients
  - At least 12 weeks post-Tx
  - 122 lost to follow-up
  - 131 pending SVR12
- 440 treated in community: 30%



# Predictors of SVR




# Predictors of SVR




UNK Cirrhotic n = 30

UNK Prior HCV Treatment n = 144

# Ribavirin Use




# Treatment Failures (n=51)



Other:  
Decompensation = 2/4  
Acute surgical intervention = 1/4  
Incarceration = 1/4



# Trend in Treatment Uptake (July 2016 – June 2018)





**Is this  
what was  
expected?**

# Reach-C Australia



The Kirby Institute. Real world efficacy of antiviral therapy in chronic hepatitis C in Australia (Issue 2). The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, July 2018 (available online at: <https://kirby.unsw.edu.au>).

Patients initiated treatment between Mar 2016 - Dec 2017



# Summary

- Over last 2 years, >3000 New Zealanders treated with VIEKIRA PAK including 30% in community
- SVR rates >96% in both community and hospital
- Rate of cirrhosis (16%) was higher than expected 10%<sup>1</sup>
  - Prioritisation of cirrhotics for treatment *or*
  - Previously underestimated prevalence
- Treatment uptake declined by 75% over past 2 years
  - Need improved diagnosis rates
  - Need simpler and pan-genotypic treatment

<sup>1</sup>HCV Epidemiology Working Group. NZMJ /vol-127-no-1407/6390

# Way forward

- Roll out REACH-C to remaining 11 DHBs
- Include all genotypes when MAVIRET is funded
- Collect resistance data from treatment failures
  - Convince PHARMAC to fund retreatment options

# Acknowledgements

- Greg Dore & Pip Marks at Kirby Institute, UNSW
- Bridget Faire (ADHB), Nicola Caine & Lauren Mabbutt (BoP DHB), Judith McLaughlin & Jenny Bourke (Canterbury DHB), Lucy Mills (CMDHB), Trish Healy, Angela Taylor, Belinda Heaphy (Nelson-Marlborough DHB), Sandra Meyst (Northland DHB), Margaret Fraser (Southern DHB), Anne Currie (Waikato DHB) Christine Hayes (Waitemata DHB) Gizelle Lopez (Capital-Coast DHB), Chris Bowden (Taranaki DHB)
- PHARMAC for provision of prescription data
- AbbVie for unrestricted grant



UNSW  
AUSTRALIA



abbvie

PHARMAC  
Pharmaceutical Management Agency